192 related articles for article (PubMed ID: 33965001)
1. Combination CFTR modulator therapy in children and adults with cystic fibrosis.
Guimbellot JS; Taylor-Cousar JL
Lancet Respir Med; 2021 Jul; 9(7):677-679. PubMed ID: 33965001
[No Abstract] [Full Text] [Related]
2. A combination therapy for cystic fibrosis.
Brodsky JL; Frizzell RA
Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
[TBL] [Abstract][Full Text] [Related]
3. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
4. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
van Koningsbruggen-Rietschel S; Naehrlich L
Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
[No Abstract] [Full Text] [Related]
5. Time for a gut check: Pancreatic sufficiency resulting from CFTR modulator use.
Megalaa R; Gopalareddy V; Champion E; Goralski JL
Pediatr Pulmonol; 2019 Aug; 54(8):E16-E18. PubMed ID: 31066218
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic benefit of ivacaftor in late cystic fibrosis caused by homozygous IVS8-5T CFTR polymorphism.
Magne F; Durupt S; Nove-Josserand R; Bey-Omar F; Laoust L; Cottin V; Durieu I; Reynaud Q
J Cyst Fibros; 2017 Jan; 16(1):89-90. PubMed ID: 27810230
[No Abstract] [Full Text] [Related]
7. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
8. A systematic Cochrane Review of correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Paediatr Respir Rev; 2019 Apr; 30():25-26. PubMed ID: 31128877
[No Abstract] [Full Text] [Related]
9. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
10. Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry.
Elborn JS; Ramsey B; Wainwright C; Boyle M
Thorax; 2016 Feb; 71(2):185-6. PubMed ID: 26506855
[No Abstract] [Full Text] [Related]
11. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
Jones AM; Barry PJ
Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
[No Abstract] [Full Text] [Related]
12. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor.
Graeber SY; Hug MJ; Sommerburg O; Hirtz S; Hentschel J; Heinzmann A; Dopfer C; Schulz A; Mainz JG; Tümmler B; Mall MA
Am J Respir Crit Care Med; 2015 Nov; 192(10):1252-5. PubMed ID: 26568242
[No Abstract] [Full Text] [Related]
13. Therapy for cystic fibrosis--the end of the beginning?
Davis PB
N Engl J Med; 2011 Nov; 365(18):1734-5. PubMed ID: 22047565
[No Abstract] [Full Text] [Related]
14. PharmGKB summary: very important pharmacogene information for CFTR.
McDonagh EM; Clancy JP; Altman RB; Klein TE
Pharmacogenet Genomics; 2015 Mar; 25(3):149-56. PubMed ID: 25514096
[No Abstract] [Full Text] [Related]
15. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
Bitonti M; Fritts L; So TY
J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
[TBL] [Abstract][Full Text] [Related]
16. Pulmonology: CFTR modulators for cystic fibrosis.
Bertoncini E; Colomb-Lippa D
JAAPA; 2013 Feb; 26(2):59-60. PubMed ID: 23409389
[No Abstract] [Full Text] [Related]
17. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
18. Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis.
McCarthy C; Brewington JJ; Harkness B; Clancy JP; Trapnell BC
Eur Respir J; 2018 Jun; 51(6):. PubMed ID: 29563174
[No Abstract] [Full Text] [Related]
19. Ivacaftor for patients with cystic fibrosis.
Wainwright CE
Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205
[TBL] [Abstract][Full Text] [Related]
20. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]